PTK2 and pulmonary fibrosis: FAK has been identified as a potential therapeutic target for lung diseases due to its overactivation, which is closely associated with various pulmonary pathologies, including lung cancer (characterized by proliferation and migration), pulmonary fibrosis (marked by fibrosis), and acute lung injury (associated with inflammation) [13,14].